Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008275 · ClinicalTrials.gov registry record · Early Phase 1
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
A Early Phase 1 study of Breast Cancer and Metastatic Triple-Negative Breast Carcinoma, sponsored by Baylor Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06008275 is a Early Phase 1 study of Breast Cancer and Metastatic Triple-Negative Breast Carcinoma that is actively recruiting participants, run by Baylor Research Institute. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06008275, a Early Phase 1 study of Breast Cancer and Metastatic Triple-Negative Breast Carcinoma, is actively recruiting participants, sponsored by Baylor Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Conditions Studied
Interventions
- DRUG Neratinib Oral Tablet
- DRUG Ruxolitinib Oral Tablet
Study Locations (1)
Texas
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06008275
The ClinicalTrials.gov registry entry for NCT06008275 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Neratinib Oral Tablet is the first listed.
NCT06008275 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06008275 about?
NCT06008275 is a clinical study titled "Neratinib in Combination With Ruxolitinib in Patients With mTNBC". The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoreg...
What is the current status of trial NCT06008275?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-09-16. Estimated completion is 2026-12.
What conditions does trial NCT06008275 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Triple-Negative Breast Carcinoma.
What interventions are being tested in trial NCT06008275?
The interventions under investigation include: Neratinib Oral Tablet (DRUG), Ruxolitinib Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06008275?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008275 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
-
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.